U.S. Markets closed

Arvinas, Inc. (ARVN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
64.69+1.69 (+2.68%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close63.00
Open63.47
Bid50.00 x 1000
Ask77.18 x 1200
Day's Range61.99 - 65.32
52 Week Range19.68 - 92.77
Volume521,188
Avg. Volume502,430
Market Cap3.162B
Beta (5Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-3.02
Earnings DateApr 26, 2021 - Apr 30, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est109.09
  • Is ARVN Stock A Buy or Sell?
    Insider Monkey

    Is ARVN Stock A Buy or Sell?

    Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]

  • Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
    GlobeNewswire

    Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021

    NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held virtually from April 10-15, 2021 and May 17-21, 2021. These presentations will describe the discovery of Arvinas’ two clinical-stage PROTAC degraders, ARV-110 and ARV-471, including the first disclosures of their structures. Details for the presentations are as follows: Title: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancerDate and Time: April 11, 2021 from 2:05 PM - 2:15 PM ETPresenter: Lawrence B. Snyder, Ph.D., Executive Director of Medicinal Chemistry at ArvinasSession Title: New Therapeutics Targeting Molecular Drivers in Cancer Title: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC® for the treatment of patients with breast cancerDate and Time: April 11, 2021 from 2:20 PM - 2:30 PM ETPresenter: Lawrence B. Snyder, Ph.D., Executive Director of Medicinal Chemistry at Arvinas Session Title: New Therapeutics Targeting Molecular Drivers in Cancer Abstracts will be available for registered attendees on the AACR website beginning on April 9, 2021. About ArvinasArvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com. Contacts for ArvinasInvestorsWill O’Connor, Stern Investor Relations ir@arvinas.com MediaKirsten Owens, Arvinas Communicationskirsten.owens@arvinas.com

  • Arvinas to Participate in Upcoming Virtual Investor Conferences
    GlobeNewswire

    Arvinas to Participate in Upcoming Virtual Investor Conferences

    NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virtual investor conferences. John Houston, Ph.D., President and Chief Executive Officer, will participate in panel discussions at both conferences. Guggenheim Targeted Protein Degradation Day panel discussion on Tuesday, March 16, 2021 at 10:30 a.m. ET33rd Annual Roth Conference panel discussion on Wednesday, March 17, 2021 at 5:00 p.m. ET A live audio webcast of each panel will be available on Arvinas’ website at www.arvinas.com. A replay of each webcast will be archived on Arvinas’ website for 30 days following the presentation. About ArvinasArvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com. Contacts for ArvinasInvestorsWill O’Connor, Stern Investor Relations ir@arvinas.com MediaKirsten Owens, Arvinas Communicationskirsten.owens@arvinas.com